The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Phase II trial of split-dose R-CHOP for older patients with DLBCL
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the rationale and interim results of a Phase II study evaluating split-dose R-CHOP for older patients with advanced-stage diffuse large B-cell lymphoma (NCT03943901). Dr Shah explains that this regimen allows older patients to receive the same dose intensity as R-CHOP-21 by using a fractionated dosing schedule improving the tolerability of this regimen. The study met its primary interim endpoint with 10 out of 14 patients achieving complete remission (CR) at the end of treatment. In addition, patients who achieved measurable residual disease (MRD) and PET/CT negativity at interim stratification and who had treatment de-escalation all remained in remission. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
